Information de reference pour ce titreAccession Number: | 01445433-200811000-00010.
|
Author: | Tavtigian, Sean V. 1,*; Byrnes, Graham B. 1; Goldgar, David E. 2; Thomas, Alun 3
|
Institution: | (1) International Agency for Research on Cancer (IARC), Lyon, France; (2) Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah; (3) Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, Utah
|
Title: | Classification of Rare Missense Substitutions, Using Risk Surfaces, With Genetic- and Molecular-Epidemiology Applications.[Article]
|
Source: | Human Mutation. 29(11):1342-1345, November 2008.
|
Abstract: | : For the Mutation Pathogenicity Special Issue
Many individually rare missense substitutions are encountered during deep resequencing of candidate susceptibility genes and clinical mutation screening of known susceptibility genes. BRCA1 and BRCA2 are among the most resequenced of all genes, and clinical mutation screening of these genes provides an extensive data set for analysis of rare missense substitutions. Align-GVGD is a mathematically simple missense substitution analysis algorithm, based on the Grantham difference, which has already contributed to classification of missense substitutions in BRCA1, BRCA2, and CHEK2. However, the distribution of genetic risk as a function of Align-GVGD's output variables Grantham variation (GV) and Grantham deviation (GD) has not been well characterized. Here, we used data from the Myriad Genetic Laboratories database of nearly 70,000 full-sequence tests plus two risk estimates, one approximating the odds ratio and the other reflecting strength of selection, to display the distribution of risk in the GV-GD plane as a series of surfaces. We abstracted contours from the surfaces and used the contours to define a sequence of missense substitution grades ordered from greatest risk to least risk. The grades were validated internally using a third, personal and family history-based, measure of risk. The Align-GVGD grades defined here are applicable to both the genetic epidemiology problem of classifying rare missense substitutions observed in known susceptibility genes and the molecular epidemiology problem of analyzing rare missense substitutions observed during case-control mutation screening studies of candidate susceptibility genes. Hum Mutat 29(11), 1342-1354, 2008.
Copyright (C) 2008 John Wiley & Sons, Inc.
|
Author Keywords: | BRCA1; BRCA2; Align-GVGD; unclassified variant; missense substitution; protein multiple sequence alignment.
|
References: | Abkevich V, Zharkikh A, Deffenbaugh A, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV. 2004. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Gen 41:492-507.
Capriotti E, Arbiza L, Casadio R, Dopazo J, Dopazo H, Marti-Renom MA. 2008. Use of estimated evolutionary strength at the codon level improves the prediction of disease-related protein mutations in humans. Hum Mutat 29:198-204.
Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nystrom M, Grimm AJ, Christodoulou J, Oetting WS, Greenblatt MS. 2007. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 28:683-693.
Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB. 2006. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027.
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. 2004. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869-872.
Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. 2007. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873-883.
Ferrer-Costa C, Orozco M, de la Cruz X. 2004. Sequence-based prediction of pathological mutations. Proteins 57:811-819.
Fitch WM, Markowitz E. 1970. An improved method for determining codon variability in a gene and its application to the rate of fixation of mutations in evolution. Biochem Genet 4:579-593.
Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. 2004. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544.
Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS; IARC Unclassified Genetic Variants Working Group. 2008. Integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29:1265-1272.
Grantham R. 1974. Amino acid difference formula to help explain protein evolution. Science 185:862-864.
Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP. 2003. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 22:1150-1163.
Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A. 2007. Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3:e26.
Kryukov GV, Pennacchio LA, Sunyaev SR. 2007. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet 80:727-739.
Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, Pfeiffer RM. 2005. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 97:998-1007.
Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper J, Waring P, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ, Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB, Brown MA. 2006. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74-83.
Lunter G, Hein J. 2004. A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics 20(Suppl 1):I216-I223.
Ng PC, Henikoff S. 2001. Predicting deleterious amino acid substitutions. Genome Res 11:863-874.
Ng PC, Henikoff S. 2003. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814.
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. 2006. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167.
Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. 2006. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873-875.
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. 2006. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239-1241.
Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G, Tavtigian SV, Goldgar DE. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis-a report from the kConFab Investigators. J Clin Oncol. 2008; 26:1657-26:1663.
Stone EA, Sidow A. 2005. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. Genome Res 15:978-986.
Sunyaev S, Ramensky V, Koch I, Lathe Wr, Kondrashov AS, Bork P. 2001. Prediction of deleterious human alleles. Hum Mol Genet 10:591-597.
Tavtigian SV, Oliphant A, Shattuck-Eidens D, Bartel PL, Thomas A, Frank TS, Pruss D, Skolnick MH. 1997. Genomic organization, functional analysis, and mutation screening of BRCA1 and BRCA2. In: Fortner JG, Sharp PA, editors. Accomplishments in cancer research, 1996. New York: Lippincott-Raven. p 189-204.
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. 2006. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295-305.
Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB; IARC Unclassified Genetic Variants Working Group. 2008. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29:1327-1336.
Wallace IM, O'Sullivan O, Higgins DG, Notredame C. 2006. M-Coffee: combining multiple sequence alignment methods with T-Coffee. Nucleic Acids Res 34:1692-1699.
Yang Z. 1998. Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 15:568-573.
Yue P, Li Z, Moult J. 2005. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 353:459-473.
|
Language: | English.
|
Document Type: | RESEARCH ARTICLE.
|
Journal Subset: | Life & Biomedical Sciences. Science.
|
ISSN: | 1059-7794
|
DOI Number: | https://dx.doi.org/10.1002/humu....- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|